GSK has completed a transformative $10.6B acquisition, adding near-term FDA decision catalysts. Traders should monitor FDA approval decisions on zidesamtinib and neladalkib later this year, which could drive significant upside. Watch for integration costs and potential guidance updates in GSK's next earnings report.
Price Chart
Executive Summary
GSK completed its $10.6B acquisition of Nuvalent, adding three lung cancer assets (zidesamtinib, neladalkib, NVL-330) with near-term FDA review decisions. The deal is a major strategic expansion into NSCLC, with multi-blockbuster potential if approved.
Key Facts
- GSK completed acquisition of Nuvalent for aggregate equity value of approximately $10.6 billion (£8.0 billion); net of cash acquired, GSK's aggregate investment is approximately $9.4 billion (£7.1 billion).
- Acquisition adds three lung cancer assets: zidesamtinib (NVL-520), neladalkib (NVL-655), and NVL-330 (phase I).
- Zidesamtinib and neladalkib are under FDA review for ROS1-positive and ALK-altered NSCLC with target decision dates later this year; both have Breakthrough Therapy and Orphan Drug Designations.
- If approved, assets are expected to launch in 2026 with multi-blockbuster potential.
- GSK CEO Luke Miels highlighted the deal accelerates entry into lung cancer and complements existing pipeline including Ris-Rez (B7-H3 ADC) in phase III.
Financial Impact
Aggregate equity value $10.6B; net cash invested $9.4B, representing ~10% of GSK's market cap.
Risk Factors
- FDA approval risk for zidesamtinib and neladalkib; any adverse regulatory decisions would impair deal value.
- Integration challenges and potential financing dilution if debt or equity issued.
- Competitive landscape in NSCLC targeted therapies (ROS1, ALK, HER2) may limit peak sales.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006663 |
| Document: 0001654954-26-006663-index-headers.html | 0001654954-26-006663 |
| Document: 0001654954-26-006663-index.html | 0001654954-26-006663 |
| Document: 0001654954-26-006663.txt | 0001654954-26-006663 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $50.01 $50.22 | ▲ +0.42% | ▼ −0.40% | $47.03 (−5.96%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 11, 2026 21d ago | 6-K | $48.13 $50.22 | ▲ +4.34% | ▲ +4.56% | $47.03 (−2.29%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Aug 26, 2026 5w ago | 6-K | $51.43 $50.44 | ▼ −1.92% | ▼ −1.80% | $47.03 (−8.56%) |
Aug 24, 2026 5w ago | 6-K | $51.78 $50.25 | ▼ −2.95% | ▼ −3.42% | $47.03 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access